Amphastar Pharmaceuticals, Inc. (AMPH) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Amphastar Pharmaceuticals, Inc. (AMPH) Healthcare & Pipeline Overview

Amphastar Pharmaceuticals, Inc. is a biopharmaceutical company specializing in injectable and inhalation products, including generic and proprietary formulations. With a focus on hospitals and care facilities across the US, China, and France, Amphastar leverages its API segment and finished pharmaceutical products to address critical healthcare needs.

What Is the Investment Thesis for AMPH?

With a P/E ratio of 13.53 and a profit margin of 11.0%, the company demonstrates financial stability. Key growth catalysts include expanding its generic and proprietary injectable product lines and increasing its presence in the API market. The company's focus on essential medications, such as Naloxone and Enoxaparin, provides a stable revenue stream. A free cash flow of $0.08 billion further supports its growth initiatives. However, investors may want to evaluate potential risks, including regulatory challenges and competition from other generic drug manufacturers. The company's ability to navigate these challenges will be crucial for sustained growth.

Based on FMP financials and quantitative analysis

AMPH Key Highlights

Market Cap of $1.04B reflects Amphastar's current valuation in the biopharmaceutical market.

• P/E Ratio of 13.53 indicates that the company may be undervalued compared to its earnings.
• Profit Margin of 11.0% demonstrates the company's ability to generate profit from its revenue.
• Gross Margin of 47.3% reflects efficient cost management in the production and sale of its pharmaceutical products.
• Free Cash Flow of $0.08B provides financial flexibility for investments in R&D and strategic acquisitions.

Who Are AMPH's Competitors?

AMPH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are AMPH's Key Strengths?

Diverse product portfolio of generic and proprietary injectables and inhalation products.

• Established presence in the United States, China, and France.
• In-house API manufacturing capabilities.
• Strong relationships with hospitals and care facilities.

What Are AMPH's Weaknesses?

Reliance on generic products, which are subject to pricing pressures.

• Limited presence in emerging markets.
• Dependence on regulatory approvals for new products.
• Potential for product recalls and liability claims.

What Could Drive AMPH Stock Higher?

Expansion of generic injectable product portfolio to drive revenue growth.

• Potential regulatory approvals for new generic drug applications.
• Increased sales of API to other pharmaceutical companies.
• Strategic acquisitions to expand product portfolio and geographic reach.

What Are the Key Risks for AMPH?

Intense competition from other generic drug manufacturers could erode market share.

• Stringent regulatory requirements and potential delays in product approvals.
• Pricing pressures from healthcare providers and payers could impact profitability.
• Product liability claims and recalls could result in significant financial losses.

What Are the Growth Opportunities for AMPH?

• Growth opportunity 1: Expansion of Generic Injectable Portfolio: Amphastar has the opportunity to expand its generic injectable product portfolio, capitalizing on the increasing demand for affordable medications. The global generic injectables market is projected to reach $70 billion by 2028. By developing and launching new generic versions of off-patent injectable drugs, Amphastar can increase its market share and revenue. This strategy requires continued investment in research and development and navigating regulatory approval processes.
• Growth opportunity 2: Increased API Sales: Amphastar can leverage its API segment to drive growth by increasing sales of recombinant human insulin and porcine insulin API. The global insulin market is expected to reach $40 billion by 2027, driven by the rising prevalence of diabetes. By expanding its API manufacturing capacity and securing supply agreements with pharmaceutical companies, Amphastar can capitalize on this growing market.
• Growth opportunity 3: Geographic Expansion into Emerging Markets: Amphastar has the opportunity to expand its geographic presence into emerging markets, such as India and Brazil. These markets offer significant growth potential due to their large populations and increasing healthcare spending. Entering these markets requires establishing local partnerships, navigating regulatory requirements, and adapting its product portfolio to local needs.
• Growth opportunity 4: Development of Proprietary Products: Investing in the development of proprietary products can provide Amphastar with higher profit margins and a competitive advantage. Focusing on innovative drug delivery systems or novel formulations can differentiate the company from generic drug manufacturers. This strategy requires significant investment in research and development and a strong intellectual property portfolio.
• Growth opportunity 5: Strategic Acquisitions: Amphastar can pursue strategic acquisitions to expand its product portfolio, geographic reach, and manufacturing capabilities. Acquiring companies with complementary products or technologies can accelerate growth and create synergies. This strategy requires careful due diligence and integration planning to ensure a successful acquisition.

What Are AMPH's Competitive Advantages?

• Specialized Manufacturing Capabilities: Expertise in manufacturing injectable and inhalation products creates a barrier to entry.
• Regulatory Expertise: Navigating complex regulatory approval processes provides a competitive advantage.
• Established Distribution Network: Existing relationships with hospitals, care facilities, and clinics facilitates product distribution.
• API Manufacturing: In-house API manufacturing provides cost advantages and supply chain control.

What Does AMPH Do?

Founded in 1996 and headquartered in Rancho Cucamonga, California, Amphastar Pharmaceuticals, Inc. has evolved into a bio-pharmaceutical company focused on developing, manufacturing, and marketing specialty pharmaceutical products. The company operates through two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). Its product portfolio includes both generic and proprietary injectable, inhalation, and intranasal products. Key products include Primatene Mist, an over-the-counter epinephrine inhalation product for temporary asthma relief, and Enoxaparin, a low molecular weight heparin used to prevent and treat deep vein thrombosis. Other notable products are Naloxone for opioid overdose, Glucagon for injection emergency kits, and Cortrosyn, a diagnostic agent for adrenocortical insufficiency. Additionally, Amphastar offers Amphadase, Epinephrine injection, lidocaine jelly and topical solutions, phytonadione injection, emergency syringe products, morphine injection, lorazepam injection, neostigmine methylsulfate injection, and Isoproterenol hydrochloride injection. The company also distributes recombinant human insulin and porcine insulin API. Amphastar serves a diverse customer base, including hospitals, care facilities, alternate care sites, clinics, and doctors' offices across the United States, China, and France.

What Products and Services Does AMPH Offer?

• Develops generic and proprietary injectable products.
• Manufactures inhalation products.
• Markets and sells pharmaceutical products in the United States, China, and France.
• Offers over-the-counter epinephrine inhalation products for asthma relief.
• Provides low molecular weight heparin to prevent and treat deep vein thrombosis.
• Supplies Naloxone for opioid overdose treatment.
• Distributes recombinant human insulin and porcine insulin API.

How Does AMPH Make Money?

• Develops and manufactures generic and proprietary pharmaceutical products.
• Sells finished pharmaceutical products to hospitals, care facilities, and clinics.
• Distributes active pharmaceutical ingredients (API) to other pharmaceutical companies.
• Generates revenue through product sales in the United States, China, and France.

What Industry Does AMPH Operate In?

Amphastar Pharmaceuticals operates within the specialty and generic drug manufacturing industry, a sector characterized by intense competition and stringent regulatory oversight. The market is driven by increasing demand for affordable medications and the expiration of patents on branded drugs. Amphastar's focus on injectable and inhalation products positions it in a niche market with specific manufacturing and regulatory requirements. The company competes with other generic drug manufacturers and faces pressure to maintain profitability while investing in research and development. The industry is also subject to evolving regulations and pricing pressures, impacting companies' financial performance.

Who Are AMPH's Key Customers?

• Care Facilities
• Alternate Care Sites
• Doctors' Offices

Company Profile

Amphastar Pharmaceuticals, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Rancho Cucamonga, US. The company is led by CEO Yongfeng Zhang. AMPH has traded publicly since 2014.

Amphastar Pharmaceuticals, Inc. Financial Trajectory

Amphastar Pharmaceuticals, Inc. (AMPH) reported $183.9M in revenue for Jun 2026, reflecting 7.4% growth compared to the prior quarter. The company recorded net income of $30.3M, with diluted EPS of $0.69. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, AMPH averaged $0.43 in diluted EPS.

How Amphastar Pharmaceuticals, Inc. Is Valued

Amphastar Pharmaceuticals, Inc. carries a market capitalization of $1.04B, placing it in the small-cap category. Analyst price targets span from $19.00 to $23.00, with a consensus of $21.25. At the current price of $23.54, that implies roughly 10% downside from the consensus target. Relative to its peer group, AMPH's quantitative score of 76/100 is above the peer average of 66/100.

Return on equity for Amphastar Pharmaceuticals, Inc. stands at 10.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.3%, showing how much profit it generates from its asset base. AMPH trades at a trailing price-to-earnings ratio of 13.53, below the Healthcare sector average of ~21.50x. A current ratio of 3.85 indicates the company holds enough short-term assets to cover its near-term obligations.

Amphastar Pharmaceuticals, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.11 places it in the grey zone, a middle ground that warrants monitoring.

Amphastar Pharmaceuticals, Inc. has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 3.5% above estimates on average.

Wall Street analysts project Amphastar Pharmaceuticals, Inc. revenue of about $747.8M for fiscal 2026, with EPS near $2.97. The estimate reflects 4 contributing analysts.

Over the past six months, Amphastar Pharmaceuticals, Inc. insiders filed 20 SEC Form 4 transactions — 5 sales and 15 purchases. On net that is roughly 157K shares acquired (about $1.8M) — insiders putting money in tends to read as conviction.

AMPH Financials

AMPH Latest News

AMPH Analyst Consensus

AMPH MoonshotScore

AMPH Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources